Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection and Sepsis in Laboring High-risk Women: 3-Arm RCT
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 756
- 试验地点
- 1
- 主要终点
- Number of Participants Who Experienced Composite Peripartum Infection or Death
研究概览
简要总结
This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.
详细描述
This 3-arm study is a large randomized clinical trial designed to evaluate the comparative effectiveness and safety of single dose oral azithromycin or combined azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and sepsis in laboring women. We have previously shown the effectiveness of azithromycin for extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at reducing these morbidities in women who have vaginal births. There is an increased risk of infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery, we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥18 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women ≥ 37 weeks' viable singleton or twin gestation in labor planning a vaginal delivery with
- •Prolonged membrane rupture (≥8 hours) or
- •Prolonged labor (≥18 hours).
排除标准
- •Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention.
- •Allergy to azithromycin or amoxicillin
- •Plan for cesarean delivery prior to enrollment
- •Fetal demise or major congenital anomaly: Major congenital anomalies may confound assessment of neonatal outcomes and every attempt will be made up front to exclude them from randomization. However, some unrecognized fetal anomalies may inevitably be randomized. These will not be excluded post-randomization from the primary (maternal outcome) analysis; they will be taken into consideration in the secondary analyses of neonatal outcomes.
研究组 & 干预措施
Azithromycin and amoxicillin placebo
Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
干预措施: Azithromycin (Drug)
Azithromycin and amoxicillin placebo
Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
干预措施: Placebo (Drug)
Azithromycin + amoxicillin
Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
干预措施: Azithromycin and amoxicillin (Drug)
Usual Care
This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants Who Experienced Composite Peripartum Infection or Death
时间窗: Up to 6 weeks after delivery
Maternal peripartum infection including chorioamnionitis, endometritis, wound infection/abscess, sepsis, and death
次要结局
- Number of Participants Who Experienced Fever(up to 6 weeks after delivery)
- Number of Participants Who Experienced Stillbirth(delivery)
- Number of Participants Who Experienced a Maternal Readmission(up to 6 weeks after delivery)
- Number of Participants Who Experienced Hypothermia(up to 6 weeks after delivery)
- Number of Participants Who Experienced Other Infection(up to 6 weeks after delivery)
- Number of Participants Who Experienced Transfusion(up to 6 weeks after delivery)
- Length of Stay(up to 6 weeks postpartum)
- Number of Participants Who Experienced a Clinic Visit(up to 6 weeks after delivery)
- Number of Participants Who Experienced Breast Infection(Up to 6 weeks after delivery)
- Number of Participants Who Needed PP Antibiotic(up to 6 weeks after delivery)
- Number of Participants Who Experienced Pyelonephritis(Up to hospital discharge)
研究者
Alan Tita
Professor and Director
University of Alabama at Birmingham
